New schizophrenia pill aims to keep symptoms at bay

NCT ID NCT07227818

Recruiting now Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether the experimental drug NBI-1117568 can delay relapse of schizophrenia symptoms compared to a placebo. About 560 adults with stable schizophrenia will first receive the drug openly, then be randomly assigned to continue it or switch to placebo. The main goal is to see how long it takes for symptoms to return.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NBI-1117568 (oral capsules)
What this could lead to: If successful, this could provide a new treatment option to help people with schizophrenia maintain stability and prevent symptom relapse.
What could go wrong: This is an early Phase 3 study, so results are not yet proven. The drug may not work better than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Neurocrine Clinical Site
RECRUITING

Garden Grove, California, 92845, United States
Neurocrine Clinical Site
RECRUITING

La Habra, California, 90631, United States
Neurocrine Clinical Site
RECRUITING

Lemon Grove, California, 91945, United States
Neurocrine Clinical Site
RECRUITING

Oceanside, California, 92056, United States
Neurocrine Clinical Site
RECRUITING

Torrance, California, 90504, United States
Neurocrine Clinical Site
RECRUITING

West Hills, California, 91307, United States
Neurocrine Clinical Site
RECRUITING

Hollywood, Florida, 33024, United States
Neurocrine Clinical Site
RECRUITING

Maitland, Florida, 32751, United States
Neurocrine Clinical Site
RECRUITING

Miami, Florida, 33122, United States
Neurocrine Clinical Site
RECRUITING

Miami, Florida, 33155, United States
Neurocrine Clinical Site
RECRUITING

Tampa, Florida, 33629, United States
Neurocrine Clinical Site
RECRUITING

West Palm Beach, Florida, 33024, United States
Neurocrine Clinical Site
RECRUITING

Atlanta, Georgia, 30318, United States
Neurocrine Clinical Site
RECRUITING

Boston, Massachusetts, 02116, United States
Neurocrine Clinical Site
RECRUITING

Flowood, Mississippi, 39232, United States
Neurocrine Clinical Site
RECRUITING

Cedarhurst, New York, 11516, United States
Neurocrine Clinical Site
RECRUITING

New York, New York, 10029, United States
Neurocrine Clinical Site
RECRUITING

New York, New York, 10036, United States
Neurocrine Clinical Site
RECRUITING

The Bronx, New York, 10461, United States
Neurocrine Clinical Site
RECRUITING

Bellevue, Washington, 98007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.